Comparison of Efficacy Between Gemcitabine/Erlotinib (GE) and Gemcitabine/Capecitabine (GX) in Unresectable Pancreatic Cancer: Retrospective, Single Center Experience, Final Report

Lignende værker

• RM-028 Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer
  af: Khatri, P., et al.
  Udgivet: (2016)
• Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
  af: Heinemann, Volker, et al.
  Udgivet: (2012)
• Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
  af: Lim, Jae Yun, et al.
  Udgivet: (2015)
• Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
  af: Chadha, Awalpreet S., et al.
  Udgivet: (2016)
• Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
  af: Furuse, Junji, et al.
  Udgivet: (2017)